ZNF503 and glioblastoma: Further analysis showed elevated ZNF503-AS2 expression in Cluster 2 (Fig 3K) and a significant difference in the distribution of highly malignant MES molecular subtypes between the two immune typing patterns (Fig 3L and 3M), as well as more GBM samples and dead patients in Cluster 2 type (Fig 3N and 3O).